|
Integrative Medicine
> Scorpion
Venom Therapy
|
|
51st Annual Meeting of the Health Physics Society, June 25-29,2006 - Providence,
Rhode Island. Abstract No. WAM-B.11
|
|
|
|
|
Meeting Abstract |
|
|
|
Radioactive Scorpion Venom Therapy
Alan M Jackson, Beth Harkness
Henry Ford Health System
|
|
|
|
|
Scorpion venom is a neurotoxin and has
been found to have an affinity for glioma cells (brain cancer).
Based on that affinity, our site joined a
phase 2 clinical trial in partnership with the Transmolecular
Corporation using a synthetic version of the scorpion venom peptide
labeled with I-131 (the 131I-TM-601 protocol).
After resection of the tumor and selection
for eligibility, patients are randomized into two groups.
One group receives the therapy three times
over a span of 3 weeks while the other group receives the therapy 6
times over a span of 6 weeks.
The weekly administration amount, 1.48 GBq
(40 mCi), is identical for each group but the patients enrolled in the
six week trial receive twice the dose of the patient in the three week
trial.
This therapy is designed to be an
outpatient procedure.
Patient release presented a number of
difficult challenges due to limited knowledge about the biological
clearance of the compound and long time span of the therapy.
Due to recent regulatory directives
regarding dose to members of the public from radiation therapy, a
special emphasis was placed on validating the dose to members of the
public.
Standard and electronic dosimetry was
provided to family members to monitor their doses.
Based on these results it is evident that
patients in the six week trial must be carefully monitored and
controlled.
|
|
|
|
|
Meeting Abstract
|
News
|
|
|
|
